Catalog No.
DHC25203
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
CD115, CSF-1 receptor, CSF1R, M-CSF-R, CSF-1-R, Proto-oncogene c-Fms, Macrophage colony-stimulating factor 1 receptor, CSF-1R, FMS
Concentration
6.3 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P07333
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
SNDX-6352, UCB-6352, CAS: 2155851-88-8
Clone ID
Axatilimab
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Axatilimab in Healthy Japanese Male Participants: Results from a Phase 1, Randomized, Double-Blind, Dose-Escalation Study., PMID:40381116
Evaluating Axatilimab as a treatment option for chronic graft-versus-host disease., PMID:40338737
Cytokines in hematopoietic cell transplantation and related cellular therapies., PMID:40074514
Treatment Response in Individual Organs Affected by Chronic Graft-Versus-Host Disease., PMID:39996711
Axatilimab., PMID:39802078
FDA-approved therapies for chronic GVHD., PMID:39786434
Semimechanistic Population PK/PD Modeling of Axatilimab in Healthy Participants and Patients With Solid Tumors or Chronic Graft-Versus-Host Disease., PMID:39704205
Axatilimab: First Approval., PMID:39551906
Axatilimab (Niktimvo) for chronic graft-versus-host disease., PMID:39509159
Current Approaches for the Prevention and Treatment of Acute and Chronic GVHD., PMID:39329708
CSF1R Blockade for Refractory Chronic Graft-versus-Host Disease., PMID:39292933
Targeting CSF1R in Chronic GVHD - Lessons in Translation., PMID:39292932
Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease., PMID:39292927
Novel Pharmacological Treatment Options of Steroid-Refractory Graft-versus-Host Disease., PMID:38094101
Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study., PMID:36459673
For research use only. Not for human or drug use.
